Literature DB >> 26546027

Pembrolizumab: a new Drug That Can Induce Exacerbations of Psoriasis.

A Sahuquillo-Torralba1, R Ballester-Sánchez2, C Pujol-Marco2, R Botella-Estrada2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26546027     DOI： 10.1016/j.ad.2015.07.012

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN： 0001-7310


× No keyword cloud information.
  6 in total

Review 1.  Cutaneous toxicities of new treatments for melanoma.

Authors:  A Boada; C Carrera; S Segura; H Collgros; P Pasquali; D Bodet; S Puig; J Malvehy
Journal:  Clin Transl Oncol       Date:  2018-05-24       Impact factor: 3.405

Review 2.  Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.

Authors:  Subashini Sharon Gnanendran; Lauren Maree Turner; James Austin Miller; Shelley Ji Eun Hwang; Andrew Charles Miller
Journal:  Curr Treat Options Oncol       Date:  2020-03-19

3.  [Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].

Authors:  S Troyanova-Slavkova; L Eickenscheidt; K Dumann; L Kowalzick
Journal:  Hautarzt       Date:  2018-08       Impact factor: 0.751

Review 4.  Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders.

Authors:  Michelle Coureau; Anne-Pascale Meert; Thierry Berghmans; Bogdan Grigoriu
Journal:  Front Med (Lausanne)       Date:  2020-05-07

5.  Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description.

Authors:  Claire van Damme; Vincent Sibaud; Josette André; Bertrand Richert; Evelyne Berlingin
Journal:  JAAD Case Rep       Date:  2021-03-02

6.  Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review.

Authors:  Marlies De Bock; Eva Hulstaert; Vibeke Kruse; Lieve Brochez
Journal:  Case Rep Dermatol       Date:  2018-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.